ProCE Banner Activity

Interactive Decision Support Tool: Expert Recommendations on Treatment for Multiple Myeloma

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with multiple myeloma with those of 5 renowned experts

Released: April 19, 2023

Begin Activity

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Joseph Mikhael

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Saad Z. Usmani

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

GlaxoSmithKline

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Regeneron Pharmaceuticals, Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD: consultant/advisor: AbbVie, Amgen, AstraZeneca, Bluebird Bio, Bristol-Myers Squibb, Jannsen, Roche-Genentech, Secura Biotherapeutics, Takeda; researcher: AbbVie, Allogene, Amgen, AstraZeneca, Bristol-Myers Squibb, Carsgen.

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD: consultant/advisor/speaker: Adaptive, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, PerView, RedMed, Regeneron, Sanofi, Takeda; researcher: Sanofi, Zentalis; stock/stock options: Magenta, Poseida; royalties or patent beneficiary: Caelum Bioscience.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: consultant: AbbVie, Bluebird, Bristol-Myers Squibb, Celgene, GSK, Janssen, Pfizer, Takeda; other financial or material support: TG Therapeutics.

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Joseph Mikhael, MD, MEd, FRCPC, FACP: consultant/advisor/speaker: Amgen, Bristol-Myers Squibb, Janssen, Karyopharm, Sanofi, Takeda.

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York

Saad Z. Usmani, MD, MBA, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Gracell, Janssen, Oncopeptides, Sanofi; researcher: AbbVie, Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Gilead, Janssen, Merck, Pharmacyclics, Sanofi.

Additional Information

Program Medium

This program has been made available online.